Soleno Therapeutics Inc. has approved updated executive compensation arrangements for its named executive officers, including increases to base salaries for fiscal year 2026, cash bonuses for fiscal year 2025, and new equity awards. The company also adopted an Executive Severance Plan covering all Vice Presidents and above. Under the plan, executives terminated without cause or for good reason outside of a change in control period will receive severance payments based on months of base salary, target bonus percentage, and COBRA coverage, with equity acceleration only applying to the CEO. During a change in control period, executives are eligible for enhanced benefits, including longer severance periods, higher bonus percentages, COBRA coverage, and full acceleration of outstanding equity awards. For example, the CEO is entitled to 24 months of salary and COBRA coverage, a 150% target bonus, and 100% equity acceleration if terminated during a change in control period, while other C-suite executives receive 18 months and Senior Vice Presidents 12 months of similar benefits.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-021229), on January 23, 2026, and is solely responsible for the information contained therein.
Comments